ReNeuron Group (Berlin: RQE.BE - news) plc <\/p>\n
(the \"Company\") <\/p>\n
Interim data from clinical trial of ReNeuron's stem cell therapy for stroke to be presented at leading scientific conference <\/p>\n
Data show no safety concerns and evidence of sustained reductions in neurological impairment and spasticity <\/p>\n
Guildford, UK, 14 June 2012: ReNeuron Group plc (the \"Company\") (LSE: RENE.L) is pleased to announce the presentation of interim data from the PISCES (Pilot Investigation of Stem Cells in Stroke) clinical trial of its ReN001 stem cell therapy for disabled stroke patients. In this open label, dose-ranging Phase I safety study, ReNeuron's ReN001 stem cell therapy is being administered in ascending doses to a total of 12 stroke patients who have been left disabled by an ischaemic stroke, the most common form of the condition. <\/p>\n
The primary aim of the study is to test the safety and tolerability of the treatment in ascending doses of the ReN001 cells, in patients with moderate to severe functional neurological impairments resulting from their stroke. The secondary aim of the study is to evaluate efficacy measures for the design of future clinical trials with ReN001, including imaging measures as well as a number of tests of sensory, motor and cognitive functions. <\/p>\n
To date, six patients have been treated in the PISCES stroke study, representing the first two of four dose cohorts. The interim data being presented are from the first five patients treated, at 2 x 12 month, 1 x six month and 2 x three month follow-up points. <\/p>\n
No cell-related adverse events or adverse immune-related responses were reported in any of the patients treated to date. A number of the patients experienced minor procedure-related adverse events such as asymptomatic bleeds or superficial scalp infections at the implantation wound site. <\/p>\n
Reductions in neurological impairment and spasticity were observed in all five patients compared with their stable pre-treatment baseline performance and these improvements were sustained in longer term follow-up. <\/p>\n
Neurological deficits were measured using the National Institutes of Health Stroke Scale (NIHSS), a higher score representing a worse deficit. Patients are required to have a NIHSS score of at least 6 to participate in the study. The pre-treatment median score for the first five patients was 8 (range 6 to 10) and the three month post-treatment median score was 4 (range 3 to 9). <\/p>\n<\/p>\n
Go here to read the rest: ReNeuron Group (Berlin: RQE.BE - news) plc (the \"Company\") Interim data from clinical trial of ReNeuron's stem cell therapy for stroke to be presented at leading scientific conference Data show no safety concerns and evidence of sustained reductions in neurological impairment and spasticity Guildford, UK, 14 June 2012: ReNeuron Group plc (the \"Company\") (LSE: RENE.L) is pleased to announce the presentation of interim data from the PISCES (Pilot Investigation of Stem Cells in Stroke) clinical trial of its ReN001 stem cell therapy for disabled stroke patients. Continue reading
\nReNeuron Group plc - PISCES Trial Interim Data<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"